2025 has been a defining year for Nami Surgical. It has been shaped by important technical progress, strategic growth, global engagement and the cultivation of the team behind our technology. Each milestone has built on the last, bringing us closer to our mission of delivering safer, more precise ultrasonic tools for robotic assisted surgery.
At the centre of this progress is the continued advancement of our miniaturised ultrasonic scalpel platform. Over the past year, the team has reached several critical technical milestones, including the development of a fully modular, smart ultrasonic driving system that enables precise control of energy delivery at the surgical site. This work represents a meaningful step forward in addressing long standing challenges within robotic surgery.
One of the most significant moments of the year was the team’s readiness for its first cadaver study, an essential step in validating our technology and progressing towards in vivo testing. Alongside this, the opening of a purpose built operating and mock clinical environment has further strengthened our ability to test, refine and learn in conditions that closely reflect real world surgical practice. Designed with flexibility, safety and insight in mind, this space reinforces our commitment to thoughtful, rigorous development.
Behind the technology, our people continue to be our greatest strength. Throughout 2025, we welcomed new expertise across engineering, operations, quality, clinical and advisory roles. From specialists in regulatory and quality systems, to CAD, transducers and mechanical engineering, each appointment has added depth to the team and supported our ability to scale in an efficient, responsible way. We have also continued to invest in emerging talent through internships, industry placements and university collaborations, recognising the importance of developing future MedTech leaders alongside our core team.
Our Operations activities have played a particularly important role in the year’s progress. Improvements to our quality management system and the expansion of in-house testing capabilities have contributed to a 265 percent reduction in vessel sealing times since April 2024. These gains reflect the close working relationship between operations, engineering and clinical teams, and the value of clear structure, coordination and communication in a fast-moving R&D environment.
Leadership and advisory strengths have also continued to grow. Over the past year, we welcomed world class expertise to our extended team and board, including experienced MedTech entrepreneurs and intellectual property leaders with a strong track record of scaling innovation globally. Their insight has strengthened our strategic direction, supported the development of our IP portfolio and helped prepare the business for international growth.
2025 has also been an important year for external recognition and industry engagement. Nami was named Business to Watch at the Women’s Enterprise Scotland Awards, recognising both the progress of the company and the leadership of our Co-founder and CTO, Rebecca Cleary. Rebecca’s appointment to the board of the Ultrasonic Industry Association further reflects Nami’s growing presence within the global ultrasonic community and our commitment to collaboration across the industry.
Internationally, the team has been active across a wide range of events, conferences and trade missions spanning Europe, North America and Asia. From major scientific and surgical symposia to participation in the TMCi Innovate UK Global Incubator Programme in Texas, these engagements have supported clinical insight, partnership development and a deeper understanding of key markets. A Scottish health tech trade mission to Japan provided particularly valuable perspective on the surgical robotics landscape and opened new conversations around collaboration and innovation.
A major milestone this year has been the opening of our 10 million dollar Series A funding round. Building on strong support from existing investors and growing market interest, this raise will support global expansion, continued R&D and the development of new clinical applications. It marks an important step in scaling our operations and moving closer to commercial readiness.
Throughout 2025, we have also placed a strong emphasis on transparency and storytelling. From welcoming partners and collaborators into our facilities to sharing behind the scenes glimpses of our work through filming and showcase days, these moments reflect our belief that innovation is built through openness and shared understanding.
Looking ahead, the pace of change in surgical innovation shows no sign of slowing. Advances in data driven precision, AI and new surgical techniques will continue to shape the landscape. What remains constant for Nami is our commitment to adaptability, collaboration and patient centred design.
2025 has been a year of momentum and meaningful progress. As we move forward, we remain focused on delivering technology that supports clinicians, improves outcomes and brings the benefits of robotic assisted surgery to more patients around the world.